Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;

 @FiercePharma: Valeant to sell $2B worth of stock to finance Bausch + Lomb buyout, plus issue $7.5B in debt. More | Follow @FiercePharma

 @EricPFierce: India's Roselabs sees lots of upside in prefilled syringes for the Indian market. Story | Follow @EricPFierce

 @CarlyHFierce: Bristol-Myers makes another emerging markets move with Simcere partnership in China. Yesterday's story | Follow @CarlyHFierce

> Teva Pharmaceutical ($TEVA) will pay $40 million in upfront cash and up to $125 in contingent payments to get drug-delivery specialist MicroDose Therapeutx to expand its respiratory business. Story

> A prospectus says Valeant Pharmaceuticals ($VRX) intends to sell about $2 billion worth of shares to help finance its $8.7 billion acquisition of Bausch + Lomb. Story

> Pfizer ($PFE), Merck ($MRK) and InSite Vision Inc. are all suing Mylan Pharmaceuticals ($MYL) for infringing patents with its plan to manufacture a generic version of their eye drug AzaSite. Report

> AbbVie ($ABBV) also is suing Mylan Pharmaceuticals for stepping on three patents with it plan to make a copycat version of the HIV drug Norvi. Report

> Two independent reviews of Medtronic's ($MDT) controversial bone product Infuse indicate it works as well as traditional bone grafts but may have more risks. Story

> South Africa's Aspen Pharmacare has offered to buy GlaxoSmithKline's ($GSK) older thrombosis drug brands, Arixtra and Fraxiparine, for an undisclosed amount and pick up a plant in France in the process. Story

Medical Device News

 @FierceMedDev: Exact raising $63.7M on rocky road to FDA approval. News | Follow @FierceMedDev

 @DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. More | Follow @DamianFierce

 @MichaelGFierce: Check out our new FierceBiotech LinkedIn page... and sign up to join the discussion! LinkedIn group page | Follow @MichaelGFierce

> Boston Scientific targets FDA with brain-stim trial. Story

> Endologix endures FDA deadly warning over recall. Item

> Globus owes $16M in J&J patent suit. Report

Biotech News

 @FierceBiotech: Analysis: Big Pharma R&D demonstrates a woeful lack of innovation. News | Follow @FierceBiotech

 @JohnCFierce: AOP spins off its 80% stake in Activartis (cancer vaccines) after Elan shareholders reject takeover bid. Release | Follow @JohnCFierce

 @RyanMFierce: In $247M Transition deal, Eli Lilly is reeling in a diabetes drug candidate that it had spun off (sort of): Yesterday's item | Follow @RyanMFierce

> R&D cutbacks loom at Millennium's Cambridge ops. Item

> Teva Pharma breaks M&A silence with bite-sized MicroDose buyout. Report

> AstraZeneca picks Cambridge site as ground zero for R&D reinvention. News

> Royalty's $8B offer wilts after Elan prevails in blocking bid. Article

Biotech Research News

 @EmilyMFierce: Have you joined the @FierceBiotech LinkedIn group yet? Connect with biotech colleagues and join the discussion: Join now | Follow @EmilyMFierce

> Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies. Report

> New genetic mutations found in families with early-onset Alzheimer's. Item

> Inovio says H7N9 bird flu vaccine effective in mice. Story

> Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. More

Pharma Manufacturing News

> French plant part of proposed GSK, Aspen deal. Item

> Roselabs taps growth of prefilled syringe in India. Report

> City forecloses on Indiana insulin plant it helped fund. Article

> Eisai adding packaging facility to U.K. plant. More

And Finally... A new study says that Canada's public drug plans fall far short of many other countries in providing access to new treatments. Story